RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024As the biotech sector rebounds, Big Pharma M&A deals are being directed towards late-stage clinical development companies, particularly those companies developing biologic therapies, like ONCY and its biologic drug platform pelareorep, that can be used in the treatment of multiple cancers, including breast, pancreatic, anal, CRC, and GI cancers, for example.